Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0001104659-22-120780

Director bought 3,389,500 shares at $12.50 ($42,368,750)

  • Director acquired 1,421,008 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

RA CAPITAL MANAGEMENT, L.P. · Director

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2022-11-17 Conversion : show line 1 in the form +994,706 994,706 I
2022-11-17 Purchase : show line 2 in the form +3,389,500 $12.50 $42,368,750 4,384,206 I
2022-11-17 Conversion : show line 3 in the form +426,302 426,302 I
Open-market purchases · 3,389,500 sh · avg $12.50 · $42,368,750

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2022-11-17 Conversion : show line 4 in the form Series B Preferred Stock −2,452,947 0 I
2022-11-17 Conversion : show line 5 in the form Series B Preferred Stock −1,051,263 0 I
Loading xslF345X03/tm2231060-1_4seq1.xml…